Summit Place Financial Advisors LLC Cuts Stake in Zoetis Inc. $ZTS

Summit Place Financial Advisors LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,261 shares of the company’s stock after selling 8,108 shares during the period. Summit Place Financial Advisors LLC’s holdings in Zoetis were worth $1,417,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the fourth quarter valued at $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the fourth quarter valued at $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter valued at $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the fourth quarter valued at $32,000. Finally, Board of the Pension Protection Fund purchased a new position in shares of Zoetis during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZTS. William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Citigroup began coverage on Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target on the stock. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $151.75.

Zoetis Price Performance

ZTS opened at $115.10 on Friday. The business’s 50-day moving average is $119.93 and its two-hundred day moving average is $124.79. Zoetis Inc. has a 1 year low of $112.97 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $48.42 billion, a PE ratio of 19.12, a price-to-earnings-growth ratio of 1.75 and a beta of 0.98.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the firm earned $1.40 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.